- Home
- DAVE vs AQST Comparison
DAVE vs AQST Comparison
Compare DAVE & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVE
- AQST
- Stock Information
- Founded
- DAVE 2017
- AQST 2004
- Country
- DAVE United States
- AQST United States
- Employees
- DAVE N/A
- AQST N/A
- Industry
- DAVE Retail: Computer Software & Peripheral Equipment
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- DAVE Technology
- AQST Health Care
- Exchange
- DAVE Nasdaq
- AQST Nasdaq
- Market Cap
- DAVE 454.6M
- AQST 473.5M
- IPO Year
- DAVE N/A
- AQST 2018
- Fundamental
- Price
- DAVE $42.79
- AQST $4.92
- Analyst Decision
- DAVE Strong Buy
- AQST Strong Buy
- Analyst Count
- DAVE 6
- AQST 7
- Target Price
- DAVE $60.00
- AQST $9.29
- AVG Volume (30 Days)
- DAVE 291.8K
- AQST 1.2M
- Earning Date
- DAVE 11-05-2024
- AQST 11-04-2024
- Dividend Yield
- DAVE N/A
- AQST N/A
- EPS Growth
- DAVE N/A
- AQST N/A
- EPS
- DAVE 2.25
- AQST N/A
- Revenue
- DAVE $292,677,000.00
- AQST $58,360,000.00
- Revenue This Year
- DAVE $26.58
- AQST $16.97
- Revenue Next Year
- DAVE $18.48
- AQST N/A
- P/E Ratio
- DAVE $19.03
- AQST N/A
- Revenue Growth
- DAVE 23.68
- AQST 25.45
- 52 Week Low
- DAVE $4.72
- AQST $1.36
- 52 Week High
- DAVE $63.50
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- DAVE 52.71
- AQST 54.44
- Support Level
- DAVE $42.90
- AQST $4.74
- Resistance Level
- DAVE $49.73
- AQST $5.04
- Average True Range (ATR)
- DAVE 3.09
- AQST 0.24
- MACD
- DAVE 0.23
- AQST -0.02
- Stochastic Oscillator
- DAVE 40.40
- AQST 55.79
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit, and finding side gigs.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.